TL;DR
KO’s priced-in re-anchor sits at $81.97 — the 2026-07-21 settled close, −3.47% below the 52-week high $84.92 (2026-07-16, still the window max; 84.7% of the range) — the third tradable session after the post-close fairlife ransomware 8-K and a two-session partial recovery off the 07-17 give-back low ($81.56 → $82.12 → $81.97). The net give-back off the 07-16 pre-8-K high has narrowed to ~$12.69B (−3.47%) from the −$14.46B one-session low, still the market’s estimate of an undisclosed quantum — the 8-K quantifies nothing — not a company-confirmed impact. Adopted EV is $385,908,285,600 (marketCap + Q1-2026 net debt $33,234M incl commercial paper); the provider EV of $336.045B is rejected — it is frozen (byte-identical across every fetch of the run) and now sits $16.63B below market cap, the inversion having widened this refresh (the reverse of last round) because the recovering cap is pulling away from the static figure (PEP’s provider EV still sits +$10.01B above its reconciled value). Strongest bull point (price-independent): the broken-looking FY2025 cash flow is a quantified, dated, final one-off — $6.1B of the $6.2B fairlife milestone paid March 2025 (FY2025 10-K) — so FCF normalizes from stated $5,296M (dividend 0.60x covered) to $11,396M (1.30x), corroborated by guided FY2026 FCF ~$12.2B, though the guidance predates the fairlife 8-K and has been neither reaffirmed nor withdrawn since. Strongest bear point (bull/bear at the trailing $81.56 anchor, comps as_of 2026-07-18): on every basis computed this run KO is the most expensive name in its comp set — 8.05x EV/revenue at the fresh $81.97 anchor (priced-in §3) vs PEP 2.42x / KDP 3.31x, earnings premium +17.8% stated / +35.6% impairment-adjusted (at the bear’s $81.56 anchor) — on the slowest FY2025 grower (+1.9% vs PEP +2.3% / KDP +8.2%), and that premium de-rates to $69.25 (−15.1%) at PEP’s earnings multiple down to $41.45 (−49.2%) at KDP’s EV/EBIT (bear de-rate targets, computed at its $81.56 anchor). Priced-in break-even, computed at $81.97: a buyer earns a non-negative 12-month total return iff (exit trailing multiple) × (delivered FY2026 comparable EPS) ≥ $79.85 (= $81.97 − the $2.12 dividend). At full delivery ($3.255 midpoint) the multiple must hold ≥ 24.53x — still BELOW both pre-print anchors (25.15x pre-Q1, 25.99x February), so full delivery returns +2.4% to +5.8% total across the pre-print anchors and −7.1% only on a de-rate to PEP earnings parity. The one crossing this refresh: the current forward multiple (25.18x) edged just above the pre-Q1 25.15x, so the pre-Q1 reversion is now a fractional price decline (−0.1%) carried positive (+2.4% total) by the $2.12 dividend alone; the February reversion stays a clean price gain (+3.2% / +5.8% total). The close still sits BELOW the February full-delivery band — 25.99x × guided $3.24–3.27 = $84.21–$84.99, and $81.97 is $2.24 (2.66%) below the lower edge, $2.63 below the $84.60 midpoint (the +0.50% recovery narrowed the gap from $2.65 / 3.14% at the low but did not close it) — so the bear’s single strongest sub-claim at the high (the prepay-in-full “inside the band” reading) stays retired (rebuttal C-R1 → C-B5, at its $81.56 anchor). The two-session recovery re-priced part of what the −3.96% give-back had discounted: the post-argument run (2026-06-25 $80.42 → 07-21 $81.97) now stands at +1.93% / ΔEV $6.67B = 48% of the ~$14B IRS tail relief a win removes (33% of the $20.385B widest win value) — up from 35% at the 07-17 low, down from 138% at the 07-16 peak — so a win is now roughly half-prepaid, ~52% still unpriced upside, while the loss branch (−4.37% guided EPS; ~$14B = 3.97% of the market cap) stays unpriced; the Marriott net add has recovered to $2.93B (0.8–1.1% of FY2025 EBIT), twenty days on with zero disclosed terms.
Watch next (from the decisive ledger and catalyst calendar):
| Window | Event | If it lands bullish | If it lands bearish |
|---|---|---|---|
| 2026-07-28, before NYSE open; call 8:30 a.m. ET (6 days out) | Q2-2026 earnings (confirmed — company IR + Business Wire 2026-06-29, re-verified 2026-07-18) — first days-clean quarter AND the first scheduled fairlife/guidance checkpoint (guidance is un-reaffirmed since the incident) | Organic-equivalent ≥ ~5% with unit case ≥ +3%, guidance held or raised, fairlife restored / immaterial (T2, T5) | Reported growth reverting toward FY2025’s +1.9%; guidance trimmed or hedged, with the incident as a candidate stated reason |
| 2026-07-30..08-03 | Q2-2026 10-Q | Q2 OCF ≥ $2,092M (⇔ H1 ≥ the clean-year $4,113M comparator) — cash normalization holding (both sides’ pre-agreed threshold) | H1 OCF below $4,113M; MD&A drags recurring; an adverse fairlife subsequent-events/contingency note |
| No scheduled date (argued 2026-06-25; docket re-checked 2026-07-18, still pending) | Eleventh Circuit decision, No. 24-13470 | Win: $6.0B deposit + $385M interest (~$1.48/share) returned, ~$14B tail removed — now ~48% prepaid on that measure, so ~52% is unpriced upside (T3) | Loss: ~$14B live (3.97% of market cap) plus guided EPS −4.37% ($3.255 → $3.113) — the unpriced branch |
| No date; fairlife 8-K filed 2026-07-16, still suspended (re-checked 2026-07-18) | fairlife US production restoration / materiality determination | A restoration 8-K with no material impact and guidance reaffirmed — closes the overhang (bull F2), suggesting the −3.96% over-reacted | US production still suspended at the print, a quantified impact, or a guidance change attributed to it — a live earnings event whose size the anchor cannot yet see (T5) |
| H2-2026 | CCBA sale close (guidance assumption, regulatory approvals pending) | On-time close keeps the guidance’s ~4% A&D arithmetic intact | Slippage or termination breaks the guidance construction (bull falsifier 5) |
| ~2027-02-09..11 | FY2026 print + February dividend action | Organic ≥ 4%, FCF ≥ $12.2B, a 65th increase funded at stable payout (T2); trailing multiple back above the $84.24–$85.02 zone on delivered EPS — falsifies the bear’s exhaustion claim (T1) | Full-year organic < 4% — FY2025’s +1.9%, not guidance, was the run-rate (bull falsifier 6) |